Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma

Tools

Sandham, David A., Barker, Lucy, Brown, Lyndon, Brown, Zarin, Budd, David, Charlton, Steven J., Chatterjee, Devnanden, Cox, Brian, Dubois, Gerald, Duggan, Nicholas, Hall, Edward, Hatto, Julia, Maas, Janet, Manini, Jodie, Profit, Rachael, Riddy, Darren, Ritchie, Catherine, Sohal, Bindi, Shaw, Duncan, Stringer, Rowan, Sykes, David A., Thomas, Matthew, Turner, Katherine L., Watson, Simon J., West, Ryan, Willard, Elisabeth, Williams, Gareth and Willis, Jennifer (2017) Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma. ACS Medicinal Chemistry Letters, 8 . pp. 582-586. ISSN 1948-5875

Full text not available from this repository.

Official URL: http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.7b00157

Abstract

Further optimization of an initial DP2 receptor antagonist clinical candidate NVPQAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2- (trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.

Item Type:	Article
RIS ID:	https://nottingham-repository.worktribe.com/output/857565
Keywords:	DP2 receptor antagonist, severe asthma, clinical candidate
Schools/Departments:	University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Life Sciences > School of Biomedical Sciences
Identification Number:	https://doi.org/10.1021/acsmedchemlett.7b00157
Depositing User:	Charlton, Steven
Date Deposited:	12 Jul 2017 10:36
Last Modified:	04 May 2020 18:43
URI:	https://eprints.nottingham.ac.uk/id/eprint/44096

Actions (Archive Staff Only)

Edit View

LoginAdmin